Phase 2b Study of JX-594 in Advanced Liver Cancer Patients Failing Sorafenib
A Phase 2b study is evaluating the efficacy of JX-594 (Pexa-Vec) combined with best supportive care in advanced HCC patients who have not responded to sorafenib.
Asset / Drug
Drug and asset intelligence for sorafenib with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.